Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.51−0.30 (-1.08%)
Close on Nov 18, 2026Market cap $1.42BP/E –Yield 0.00%
Immunocore revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Immunocore's revenue for the twelve months ending Jun 30, 2026 was $430.78M, up 21.0% year over year. For fiscal 2025 it was $400.02M, up 29.0% from the year before. The highest annual figure on record is $400.02M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $400.02M | +29.0% |
| FY2024 | Dec 31, 2024 | $310.20M | +24.4% |
| FY2023 | Dec 31, 2023 | $249.43M | +43.1% |
| FY2022 | Dec 31, 2022 | $174.36M | +377.9% |
| FY2021 | Dec 31, 2021 | $36.48M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $115.93M | +18.3% |
| Q1 FY2026 | Mar 31, 2026 | $106.68M | +13.6% |
| Q4 FY2025 | Dec 31, 2025 | $104.48M | +24.3% |
| Q3 FY2025 | Sep 30, 2025 | $103.69M | +29.2% |
| Q2 FY2025 | Jun 30, 2025 | $97.96M | +29.9% |
| Q1 FY2025 | Mar 31, 2025 | $93.88M | +33.2% |
| Q4 FY2024 | Dec 31, 2024 | $84.05M | +19.8% |
| Q3 FY2024 | Sep 30, 2024 | $80.25M | +23.7% |
| Q2 FY2024 | Jun 30, 2024 | $75.40M | +26.2% |
| Q1 FY2024 | Mar 31, 2024 | $70.50M | +29.0% |
| Q4 FY2023 | Dec 31, 2023 | $70.16M | – |
| Q3 FY2023 | Sep 30, 2023 | $64.85M | – |
| Q2 FY2023 | Jun 30, 2023 | $59.76M | – |
| Q1 FY2023 | Mar 31, 2023 | $54.66M | – |
See a number that looks wrong?